Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
Close · 3M
-40.38%
Held by 0 AI ETFs
None of the tracked AI ETFs currently hold this name.
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
The Qraft AI ranking engine, driving LQAI's US large-cap core universe selection, likely removed Zoetis Inc. (ZTS) due to a substantial deterioration in its recent market performance. As an ETF maintaining a portfolio of approximately 100 US large caps and rebalancing weekly, LQAI’s methodology enables prompt adjustments to its holdings. The stock’s significant 30-day return of -29.5% would have rapidly diminished its attractiveness within the AI’s core large-cap selection framework, which prioritizes names without heavy factor tilts. Despite ZTS reporting a 62.41% ROE, this rapid re-evaluation, culminating in its removal on June 9th, demonstrates the Qraft AI’s responsiveness when a stock approaches 48% of its 52-week high, ensuring the portfolio reflects current AI-generated rankings.
weight 0.440% → 0 (exited)·stock down 0.8% in the 30 days before
The Qraft AI ranking engine, central to LQAI’s AI-driven selection method for its ~100 US large-cap core portfolio, has systematically decreased its weight in Zoetis (ZTS) over several weekly rebalances. This consistent de-prioritization suggests the AI is reacting to significant market signals for the healthcare company, where ZTS has experienced a -36.5% return over the last 30 days. Despite ZTS reporting a 62.41% ROE, the fund’s AI-driven approach, designed for continuous data assessment rather than fixed factor tilts, appears to be reflecting the persistent negative price momentum in its evolving security rankings, leading to the consecutive reduction from 0.44% to 0.42%.
weight 0.450% → 0.420% (-0.030 pp)·stock down 32.9% in the 30 days before
ZTS, a Health Care sector company, exhibits a PER of 12.47 and a PBR of 16.65, with a high ROE of 62.41% alongside revenue growth of 2.4%. For LQAI, which aims for core large-cap selection with an AI-driven approach balancing various factors, these metrics present a mixed profile of profitability and value. However, the stock’s dramatic price erosion, including a -34.2% 30-day return and its current $79.48 price representing just 47% of its 52-week high, likely altered its ranking within Qraft’s selection engine. This significant price decline appears to have directly triggered LQAI’s consecutive weight decrease in ZTS starting May 26, aligning with the ETF’s weekly rebalancing and its sensitivity to evolving market dynamics for its ~100 US large-cap holdings.
weight 0.450% → 0.430% (-0.020 pp)·stock down 32.6% in the 30 days before
ZTS shares, currently priced at $78.92, are trading near their 52-week low and represent 46% of their 52-week high, following severe price declines exceeding 34% in the past 30 days. This significant price compression likely triggered Qraft’s AI ranking system, which LG-Qraft employs for LQAI’s weekly rebalancing within its US large-cap core universe. The AI model appears to have identified ZTS as a compelling candidate, potentially weighing its underlying financial characteristics—specifically a PER of 12.52 and a 62.41% return on equity—against the considerable recent market depreciation. Following the initial entry at 0.44% on May 12th, the subsequent consecutive increases in ZTS’s portfolio weight, rising to 0.46%, suggest the AI’s growing conviction that the stock represents a strong opportunity at this low price point.
weight 0.420% → 0.460% (+0.040 pp)·stock down 35.7% in the 30 days before
The LQAI ETF, utilizing Qraft's AI ranking engine for its weekly rebalances, initiated a position in Zoetis (ZTS) around May 12th as part of its ~100 US large-cap core universe. This AI-driven selection, not beholden to heavy factor tilts, likely identified ZTS after its substantial price decrease, currently trading at $77.72, which is only 46% of its 52-week high. The consecutive weight increases, from 0.44% to 0.45% by May 18th, imply the AI continued to rank ZTS favorably during its subsequent weekly assessments. Such a move suggests the model prioritizes underlying business fundamentals, evidenced by ZTS's significant 62.41% return on equity, even amidst the recent market downturn.
weight 0.420% → 0.450% (+0.030 pp)·stock down 36.5% in the 30 days before
The AI ETF likely initiated a position in ZTS due to its exceptional Return on Equity (ROE) of 62.41%, indicating strong profitability and efficient capital use, possibly at an attractive valuation given its relatively low PER of 12.2. This suggests the AI model prioritizes companies with high financial efficiency and quality earnings. For retail investors, this highlights the importance of analyzing profitability metrics like ROE alongside traditional valuation multiples to identify high-quality companies that are efficiently generating shareholder value.
weight 0 → 0.440% (new)·stock down 35.9% in the 30 days before
The AI ETF likely divested from ZTS due to a significant overvaluation, highlighted by its extremely high Price-to-Book ratio of 16.65 and modest revenue growth of just 2.28%, indicating its price was not justified by its current growth trajectory. For retail investors, this illustrates that strong profitability (high ROE) alone does not always warrant a premium valuation if growth is stagnant and the stock is expensive on other metrics.
weight 0.110% → 0 (exited)·stock down 4.5% in the 30 days before